Highest-materiality recent filing
Nasdaq confirmed EUDA regained compliance with Listing Rule 5635(c) after CEO forfeited 271,867 shares to eliminate the discount on a $850,306 loan settlement.
EUDA amends prepaid forwards, issues 1.6M shares; adjusts CEO settlement to $1.47/share
Supplemental Agreement with CEO Dr. Kelvin Chen: 578,439 shares at $1.47/share to settle $850k loan; 271,867 shares forfeited.
EUDA Health issues ~3.26M shares to settle debts, convert notes, and raise $940K
Issued 1.62M settlement shares to extinguish $1.24M in debt and CEO claim ($850K).
EUDA Health board dispute escalates; director Chia removed, dissident resolutions rejected
Board removed Leonard Chee Hyong Chia as director on May 14, 2023, citing disruptive conduct.
EUDA Health receives Nasdaq delisting notice for failure to file Q1 2023 10-Q
Received delinquency notice from Nasdaq on May 18, 2023 for not filing Q1 2023 Form 10-Q.
EUDA Health receives Nasdaq delinquency notice for late 10-K filing
Nasdaq Notice received April 5, 2023 for failure to timely file FY 2022 10-K.
EUDA Health completes business combination with 8i Acquisition 2 Corp.; now public on Nasdaq
Business combination closed Nov 17, 2022; 8i Acquisition 2 renamed EUDA Health Holdings Limited.
Prepaid Forward Agreement with Alto Opportunity Master Fund for up to 1,125,000 ordinary shares to help ensure Nasdaq listing requirements for the EUDA Health combination.
8i enters prepaid forward agreement for up to 1.4M shares; 8.2M shares redeemed at ~$10.08
Prepaid Forward Agreement with institutional investor: may purchase up to 1,400,000 shares to hold for benefit of 8i or EUDA post-close.
8i Acquisition 2 shareholders approve EUDA Health business combination; 8.2M shares redeemed
All proposals approved at Nov 10 special meeting: business combination, name change to EUDA Health Holdings, stock issuance, and director election.
Forward Purchase Agreement with Greentree for up to 125,000 shares at $10.41 each, on 60th day post-closing.
8i Acquisition 2 Corp. amends SPAC deal with EUDA Health; consideration cut to $140M
Initial consideration reduced to $140M, payable in LAX ordinary shares at $10.00 per share.
LAX signs $550M SPAC merger with EUDA Health in all-stock deal
Initial consideration of $550M in LAX shares at $10 per share; up to 9M additional earnout shares at $15, $20, $25 thresholds.
On June 6, 2023, the Board of Directors of the Company (the “ Board ”) appointed an incumbent director, Alfred Lim, as the Company’s Executive Director, effective immediately.
Mr. David Capes and Mr. Leonard Chee Hyong Chia were removed from the Company’s Board of Directors effective May 11, 2023 and May 14, 2023, respectively.
the Board comprising of Dr. Kelvin Chen, the Company’s Chief Executive Officer, and two independent directors, Mr. Eric Lew and Mr. Alfred Lim voted unanimously to approve the appointment of Mr. Ajay Kumar Rajpal, an existing shareholder of the Company and Dr. Kong-Yew Wong as Class I directors of the Company to fill the vacancies as a result of Mr. Capes’ and Mr. Chia’s removal.
the Board comprising of Dr. Kelvin Chen, the Company’s Chief Executive Officer, and two independent directors, Mr. Eric Lew and Mr. Alfred Lim voted unanimously to approve the appointment of Mr. Ajay Kumar Rajpal, an existing shareholder of the Company and Dr. Kong-Yew Wong as Class I directors of the Company to fill the vacancies as a result of Mr. Capes’ and Mr. Chia’s removal.
Mr. David Capes and Mr. Leonard Chee Hyong Chia were removed from the Company’s Board of Directors effective May 11, 2023 and May 14, 2023, respectively.
the Register Board voted in favor of removing Leonard Chee Hyong Chia as a director of the Company effective immediately.
the Board appointed Mr. Lew Chern Yong (Eric) as Chairman of the Board, member and Chairman of the Audit Committee, and Chairman of the Corporate Governance and Nominating Committee, which appointments Mr. Lew accepted effective immediately.
the Board approved a vote to remove David Capes as a director of the Company effective immediately.
Effective March 12, 2023, Mr. Lew Chern Yong (Eric) accepted appointment to serve on the Board of Directors (the “Board” ) of EUDA Health Holdings Limited (the “Company” ).
the vacancy as a result of Mr. Gerald Lim’s resignation.
Effective March 1, 2023, Gerald Lim resigned as a member of the Board of Directors
Mr. Chee Hyong Leonard Chia accepted the appointment to serve as a Class II director of the Company to fill in the vacancy as result of Mr. Chan’s resignation, effective immediately.
Max materiality 0.85 · Median 0.53 · Most common event other_material